A multicenter, retrospective, observational cohort study of lamivudine plus dolutegravir dual therapy in HIV-1-infected patients
Latest Information Update: 15 Sep 2022
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2022 Results published in the JAIDS
- 15 Sep 2022 New trial record